oncology
Breast Cancer

Neratinib approved as adjuvant therapy in early HER2 breast cancer

Neratinib (Nerylnx) has been approved by the TGA as extended adjuvant treatment to prevent relapse in women with HER2+ breast cancer. The tyrosine kinase inhibitor is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy. The sponsor, Specialised Therapeutics, says it is currently applying ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic